We maximise the value of our product pipeline via the seamless integration of our highly differentiated device platforms, our class-leading formulation capability, and our clinical development and regulatory expertise.
In addition to our industry-leading device platforms, Vectura has outstanding formulation capabilities to match. Our deep expertise provides us with competitive advantage in the development of generics for asthma and COPD. Beyond this, we can leverage our proprietary particle engineering technologies, or skills in liquid formulation, to develop innovative products. These can be based on the significantly enhanced delivery of known respiratory molecules, or by re-purposing established drugs – normally delivered orally or via injection – in inhaled format to treat niche diseases.
In particular, liquid formulation development has been a growth area for Vectura since the acquisition of our highly differentiated smart nebulisers. The technical requirements of specific delivery technologies, the properties of the drugs we are interested in developing, and the patient needs in specific disease areas mean we must have capability in solution and suspension approaches for small molecules and biologics in order to create new and improved therapies.